

Jin Won Kim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3045389/publications.pdf>

Version: 2024-02-01

144
papers

2,568
citations

186265
28
h-index

254184
43
g-index

150
all docs

150
docs citations

150
times ranked

4353
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjuvant Chemotherapy for Gastric Cancer Patients with Mismatch Repair Deficiency or Microsatellite Instability: Systematic Review and Meta-Analysis. <i>Annals of Surgical Oncology</i> , 2022, 29, 2324-2331.	1.5	14
2	ASO Author Reflections: Adjuvant Chemotherapy Should not be Omitted for Gastric Cancer Patients with Mismatch Repair Deficiency or Microsatellite Instability. <i>Annals of Surgical Oncology</i> , 2022, 29, 2332-2333.	1.5	0
3	Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma. <i>Liver International</i> , 2022, 42, 674-681.	3.9	39
4	Cetuximab resistance induced by hepatocyte growth factor is overcome by MET inhibition in KRAS, NRAS, and BRAF wild-type colorectal cancers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2995-3005.	2.5	5
5	Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group. <i>Cancer Research and Treatment</i> , 2022, 54, 1-9.	3.0	9
6	Clinical characteristics and disease course of splanchnic vein thrombosis in gastrointestinal cancers: A prospective cohort study. <i>PLoS ONE</i> , 2022, 17, e0261671.	2.5	4
7	Safety and efficacy of intraperitoneal paclitaxel plus systemic FOLFOX for gastric cancer with peritoneal metastasis: Phase I results.. <i>Journal of Clinical Oncology</i> , 2022, 40, 309-309.	1.6	0
8	Randomized phase II study of nalicap (nal-IRI/capecitabine) compared to NAPOLI (nal-IRI/5-FU/LV) in gemcitabine-pretreated advanced pancreatic cancer: Trial-in-progress.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS621-TPS621.	1.6	0
9	Biomarker-oriented study of pembrolizumab in combination with chemotherapy in chemotherapy-naïve advanced pancreatic cancer: A phase 2 trial-in-progress.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS639-TPS639.	1.6	0
10	Phase II study of sitravatinib in combination with tislelizumab in patients with advanced biliary tract cancer who have failed to at least 1 prior systemic treatment: Trial in progress.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS490-TPS490.	1.6	2
11	Sex-based differences in histology, staging, and prognosis among 2983 gastric cancer surgery patients. <i>World Journal of Gastroenterology</i> , 2022, 28, 933-947.	3.3	14
12	Safety and Efficacy of Intraperitoneal Paclitaxel Plus Intravenous Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) for Gastric Cancer with Peritoneal Metastasis. <i>Annals of Surgical Oncology</i> , 2022, 29, 5084-5091.	1.5	8
13	Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 522-532.	8.1	149
14	Treatment patterns of thrombopoietin receptor agonists among adults with primary immune thrombocytopenia: A Korean nationwide population-based study. <i>Thrombosis Research</i> , 2022, 213, 114-118.	1.7	0
15	ASO Visual Abstract: Safety and Efficacy of Intraperitoneal Paclitaxel Plus Intravenous Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) for Gastric Cancer with Peritoneal Metastasis. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0
16	Performance of clinician prediction of survival in oncology outpatients with advanced cancer. <i>PLoS ONE</i> , 2022, 17, e0267467.	2.5	4
17	Effectiveness of oral fluoropyrimidine monotherapy as adjuvant chemotherapy for high-risk stage II colon cancer. <i>Annals of Surgical Treatment and Research</i> , 2022, 102, 271.	1.0	3
18	Health-related quality of life in patients treated with gemcitabine/cisplatin and durvalumab ± tremelimumab in chemotherapy-naïve advanced biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4117-4117.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Regional subgroup analysis of the phase 3 TOPAZ-1 study of durvalumab (D) plus gemcitabine and cisplatin (GC) in advanced biliary tract cancer (BTC).. Journal of Clinical Oncology, 2022, 40, 4075-4075.	1.6	7
20	Trastuzumab plus FOLFOX for gemcitabine/cisplatin refractory HER2-positive biliary tract cancer: A multi-institutional phase II trial of the Korean Cancer Study Group (KCSG-HB19-14).. Journal of Clinical Oncology, 2022, 40, 4096-4096.	1.6	1
21	Effectiveness of Combining Bevacizumab With First-Line Chemotherapy Regimens for Metastatic Colorectal Cancer in Real-World Practice. Clinical Colorectal Cancer, 2021, 20, 101-112.e6.	2.3	4
22	Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial). Gastric Cancer, 2021, 24, 156-167.	5.3	29
23	The prognostic role of soluble transforming growth factor- β 2 and its correlation with soluble programmed death-1 ligand 1 in biliary tract cancer. Liver International, 2021, 41, 388-395.	3.9	4
24	Pneumocystis jirovecii pneumonia in diffuse large B-cell Lymphoma treated with R-CHOP. Mycoses, 2021, 64, 60-65.	4.0	7
25	A target-mediated drug disposition population pharmacokinetic model of GC1118, a novel anti-EGFR antibody, in patients with solid tumors. Clinical and Translational Science, 2021, 14, 990-1001.	3.1	0
26	Prevalence and Predictive Factors for Upfront Dose Reduction of the First Cycle of First-Line Chemotherapy in Older Adults with Metastatic Solid Cancer: Korean Cancer Study Group (KCSG) Multicenter Study. Cancers, 2021, 13, 331.	3.7	4
27	A single-arm feasibility study of gradual dose de-escalation of antiemetic dexamethasone for older patients receiving chemotherapy. Journal of Geriatric Oncology, 2021, 12, 922-929.	1.0	1
28	Different effects of p53 protein overexpression on the survival of gastric cancer patients according to Lauren histologic classification: a retrospective study. Gastric Cancer, 2021, 24, 844-857.	5.3	14
29	A phase II trial of trastuzumab plus modified-FOLFOX for gemcitabine/cisplatin refractory HER2-positive biliary tract cancer (BTC): Multi-institutional study of the Korean Cancer Study Group (KCSG-HB19-14).. Journal of Clinical Oncology, 2021, 39, TPS4161-TPS4161.	1.6	4
30	DNA-damage response-umbrella study of the combination of ceralasertib and olaparib, or ceralasertib and durvalumab in advanced biliary tract cancer: A phase 2 trial-in-progress.. Journal of Clinical Oncology, 2021, 39, TPS4166-TPS4166.	1.6	2
31	Adjuvant chemotherapy for gastric cancer patients with mismatch repair deficiency or microsatellite instability.. Journal of Clinical Oncology, 2021, 39, e16004-e16004.	1.6	0
32	Gastrointestinal cancer treatment with immune checkpoint inhibitors. Journal of the Korean Medical Association, 2021, 64, 342-348.	0.3	0
33	Correlation between tumor infiltrating immune cells and peripheral regulatory T cell determined using methylation analyses and its prognostic significance in resected gastric cancer. PLoS ONE, 2021, 16, e0252480.	2.5	7
34	The Enhanced Inhibitory Effect of Estrogen on PD-L1 Expression Following Nrf2 Deficiency in the AOM/DSS Model of Colitis-Associated Cancer. Frontiers in Oncology, 2021, 11, 679324.	2.8	4
35	A Prognostic Model to Facilitate Palliative Care Referral in Oncology Outpatients. Cancer Research and Treatment, 2021, , .	3.0	1
36	A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy. European Journal of Cancer, 2021, 154, 288-295.	2.8	26

#	ARTICLE	IF	CITATIONS
37	A phase II study of gemcitabine, erlotinib and S-1 in patients with advanced pancreatic cancer. <i>Journal of Cancer</i> , 2021, 12, 912-917.	2.5	5
38	Gender Differences in Patients with Metastatic Pancreatic Cancer Who Received FOLFIRINOX. <i>Journal of Personalized Medicine</i> , 2021, 11, 83.	2.5	8
39	R-MPV followed by high-dose chemotherapy with thiotepa-based and autologous stem cell transplantation for newly diagnosed primary central nervous system lymphoma: a single-center experience. <i>Blood Research</i> , 2021, 56, 285-292.	1.3	3
40	Amphiregulin can predict treatment resistance to palliative first-line cetuximab plus FOLFIRI chemotherapy in patients with RAS wild-type metastatic colorectal cancer. <i>Scientific Reports</i> , 2021, 11, 23803.	3.3	4
41	The association between changes in symptoms or quality of life and overall survival in outpatients with advanced cancer. <i>Annals of Palliative Medicine</i> , 2021, .	1.2	1
42	Conversion Surgery in Metastatic Gastric Cancer and Cancer Dormancy as a Prognostic Biomarker. <i>Cancers</i> , 2020, 12, 86.	3.7	11
43	Polypharmacy, Inappropriate Medication Use, and Drug Interactions in Older Korean Patients with Cancer Receiving First-Line Palliative Chemotherapy. <i>Oncologist</i> , 2020, 25, e502-e511.	3.7	32
44	Symptom burden and characteristics of patients who die in the acute palliative care unit of a tertiary cancer center. <i>Annals of Palliative Medicine</i> , 2020, 9, 216-223.	1.2	4
45	PI3K-targeting strategy using alpelisib to enhance the antitumor effect of paclitaxel in human gastric cancer. <i>Scientific Reports</i> , 2020, 10, 12308.	3.3	20
46	Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 654-659.	1.3	18
47	PI3K p110 α Blockade Enhances Anti-Tumor Efficacy of Abemaciclib in Human Colorectal Cancer Cells. <i>Cancers</i> , 2020, 12, 2500.	3.7	4
48	Conversion surgery after cetuximab or bevacizumab plus FOLFIRI chemotherapy in colorectal cancer patients with liver- and/or lung-limited metastases. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2399-2410.	2.5	10
49	Effect of <i>Helicobacter pylori</i> eradication after subtotal gastrectomy on the survival rate of patients with gastric cancer: follow-up for up to 15 years. <i>Gastric Cancer</i> , 2020, 23, 1051-1063.	5.3	20
50	Regorafenib in patients with advanced Child-Pugh B hepatocellular carcinoma: A multicentre retrospective study. <i>Liver International</i> , 2020, 40, 2544-2552.	3.9	32
51	Korean red ginseng for cancer-related fatigue in colorectal cancer patients with chemotherapy: A randomised phase III trial. <i>European Journal of Cancer</i> , 2020, 130, 51-62.	2.8	34
52	TDP1 and TOP1 Modulation in Olaparib-Resistant Cancer Determines the Efficacy of Subsequent Chemotherapy. <i>Cancers</i> , 2020, 12, 334.	3.7	6
53	Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D) \pm tremelimumab (T) and gemcitabine/cisplatin (GemCis) in chemo-naïve advanced biliary tract cancer (aBTC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 4520-4520.	1.6	63
54	Adjuvant Chemotherapy in Microsatellite Instability-High Gastric Cancer. <i>Cancer Research and Treatment</i> , 2020, 52, 1178-1187.	3.0	12

#	ARTICLE	IF	CITATIONS
55	A randomized phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4603-4603.	1.6	5
56	Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: Multicenter study of the Korean Cancer Study Group (KCSG).. <i>Journal of Clinical Oncology</i> , 2020, 38, 4624-4624.	1.6	0
57	A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First-line Therapy (KCSG ST10-01). <i>Oncologist</i> , 2019, 24, 18-e24.	3.7	25
58	Development and Validation of an Easy-to-Implement, Practical Algorithm for the Identification of Molecular Subtypes of Gastric Cancer: Prognostic and Therapeutic Implications. <i>Oncologist</i> , 2019, 24, e1321-e1330.	3.7	20
59	Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS/RAF/MEK/ERK pathway: phase Ib study. <i>British Journal of Cancer</i> , 2019, 121, 332-339.	6.4	19
60	A First-in-Human Phase I Study of GC1118, a Novel Anti-Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors. <i>Oncologist</i> , 2019, 24, 1037-e636.	3.7	4
61	Prognostic implication of ABC transporters and cancer stem cell markers in patients with stage III colon cancer receiving adjuvant FOLFOX chemotherapy. <i>Oncology Letters</i> , 2019, 17, 5572-5580.	1.8	9
62	Clinical characteristics and outcomes of patients enrolled in clinical trials compared with those of patients outside clinical trials in advanced gastric cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 158-165.	1.1	3
63	Serum biomarkers for predicting overall survival and early mortality in older patients with metastatic solid tumors. <i>Journal of Geriatric Oncology</i> , 2019, 10, 749-756.	1.0	13
64	Identification of a potentially avoidable cardiopulmonary resuscitation in hematology and oncology wards. <i>BMC Palliative Care</i> , 2019, 18, 93.	1.8	3
65	Trastuzumab Specific Epitope Evaluation as a Predictive and Prognostic Biomarker in Gastric Cancer Patients. <i>Biomolecules</i> , 2019, 9, 782.	4.0	7
66	Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement. <i>Cells</i> , 2019, 8, 1538.	4.1	7
67	Acute pulmonary thromboembolism caused by factor V Leiden mutation in South Korea. <i>Medicine (United States)</i> , 2019, 98, e16318.	1.0	1
68	Incidence and predictors of venous thromboembolism in medically ill hospitalized elderly cancer patients: a prospective observational study. <i>Supportive Care in Cancer</i> , 2019, 27, 2507-2515.	2.2	8
69	Somatic mutational profiles of stage II and III gastric cancer according to tumor microenvironment immune type. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 12-22.	2.8	11
70	Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 223-239.	3.0	13
71	Prospective Validation of The Korean Cancer Study Group Geriatric Score (KG)-7, a Novel Geriatric Screening Tool, in Older Patients with Advanced Cancer Undergoing First-line Palliative Chemotherapy. <i>Cancer Research and Treatment</i> , 2019, 51, 1249-1256.	3.0	5
72	The prognostic role of soluble transforming growth factor- β 2 (sTGFB) and soluble programmed death-ligand 1 (sPDL1) in biliary tract cancer patients treated with binimetinib and capecitabine.. <i>Journal of Clinical Oncology</i> , 2019, 37, 257-257.	1.6	0

#	ARTICLE	IF	CITATIONS
73	The prognostic role of soluble transforming growth factor- β 2 related with soluble programmed death-ligand 1 in biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4094-4094.	1.6	2
74	Symptom burden and characteristics of patients who die in the acute palliative care unit of a tertiary cancer center.. <i>Journal of Clinical Oncology</i> , 2019, 37, 53-53.	1.6	0
75	Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy. <i>Annals of Oncology</i> , 2018, 29, 1220-1226.	1.2	36
76	Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. <i>Gastric Cancer</i> , 2018, 21, 473-480.	5.3	21
77	S-1-Induced Lacrimal Drainage Obstruction and Its Association with Ingredients/Metabolites of S-1 in Tears and Plasma: A Prospective Multi-institutional Study. <i>Cancer Research and Treatment</i> , 2018, 50, 30-39.	3.0	12
78	Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer. <i>PLoS ONE</i> , 2018, 13, e0209104.	2.5	13
79	Effect of Early Adjuvant Chemotherapy on Survival of Advanced Gastric Cancer Patients: a Propensity Score-matched Analysis. <i>Journal of Gastric Cancer</i> , 2018, 18, 58.	2.5	9
80	A population-based outcomes study of patients with metastatic gastric cancer receiving second-line chemotherapy: A nationwide health insurance database study. <i>PLoS ONE</i> , 2018, 13, e0205853.	2.5	10
81	BCJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3164.	4.1	17
82	Impact of Tumor Regression Grade as a Major Prognostic Factor in Locally Advanced Rectal Cancer after Neoadjuvant Chemoradiotherapy: A Proposal for a Modified Staging System. <i>Cancers</i> , 2018, 10, 319.	3.7	45
83	Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study. <i>PLoS ONE</i> , 2018, 13, e0198544.	2.5	21
84	Predicting cumulative incidence of adverse events in older patients with cancer undergoing first-line palliative chemotherapy: Korean Cancer Study Group (KCSG) multicentre prospective study. <i>British Journal of Cancer</i> , 2018, 118, 1169-1175.	6.4	25
85	Diagnostic Yield and False-Referral Rate of Staging Chest CT in Patients with Colon Cancer. <i>Radiology</i> , 2018, 289, 535-545.	7.3	10
86	Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells. <i>Cancer Letters</i> , 2018, 430, 123-132.	7.2	52
87	Phase Ib study of binimetinib (MEK162) in combination with capecitabine in gemcitabine-pretreated advanced biliary tract cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4079-4079.	1.6	1
88	Correlation between tumor infiltrating immune cells and peripheral regulatory T cell determined by methylation analyses and its prognostic significance in gastric cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 66-66.	1.6	0
89	Liver and/or lung metastasectomy after cetuximab or bevacizumab+FOLFIRI chemotherapy in patients (pts) with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 843-843.	1.6	0
90	Epidemiology and management of primary immune thrombocytopenia: A nationwide population-based study in Korea. <i>Thrombosis Research</i> , 2017, 155, 86-91.	1.7	46

#	ARTICLE	IF	CITATIONS
91	Prognostic value of p21-activated kinase 4 in resected pancreatic cancer. <i>Apmis</i> , 2017, 125, 699-707.	2.0	12
92	Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative relative dose intensity. <i>European Journal of Cancer</i> , 2017, 76, 125-133.	2.8	38
93	Multidisciplinary management of intrahepatic cholangiocarcinoma: Current approaches. <i>Surgical Oncology</i> , 2017, 26, 146-152.	1.6	40
94	Comparison of efficacy and tolerance between combination therapy and monotherapy as first-line chemotherapy in elderly patients with advanced gastric cancer: Study protocol for a randomized controlled trial. <i>Contemporary Clinical Trials Communications</i> , 2017, 8, 55-61.	1.1	1
95	Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5671-5678.	7.0	121
96	Systemic inflammation is associated with the density of immune cells in the tumor microenvironment of gastric cancer. <i>Gastric Cancer</i> , 2017, 20, 602-611.	5.3	76
97	EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells. <i>Yonsei Medical Journal</i> , 2017, 58, 9.	2.2	30
98	Differences in the Clinical Characteristics of Rapid Response System Activation in Patients Admitted to Medical or Surgical Services. <i>Journal of Korean Medical Science</i> , 2017, 32, 688.	2.5	14
99	EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release. <i>Oncotarget</i> , 2017, 8, 63901-63910.	1.8	30
100	Korean red ginseng to improve cancer-related fatigue in colorectal cancer patients with FOLFOX chemotherapy: A randomized, double-blind, placebo-controlled, parallel, multicenter trial, NCT02039635. <i>Journal of Clinical Oncology</i> , 2017, 35, 10008-10008.	1.6	3
101	Updated results of a phase II study of gemcitabine, erlotinib, and S-1 in patients with advanced pancreatic cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, e15778-e15778.	1.6	2
102	Predicting cumulative incidence of chemotherapy toxicity in older patients with cancer: Korean Cancer Study Group prospective cohort study (KCSG) PC 13-09. <i>Journal of Clinical Oncology</i> , 2017, 35, e21539-e21539.	1.6	1
103	Early versus delayed initiation of adjuvant treatment for pancreatic cancer. <i>PLoS ONE</i> , 2017, 12, e0173960.	2.5	21
104	Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients. <i>Oncotarget</i> , 2017, 8, 26356-26367.	1.8	54
105	PIK3CA mutations are associated with increased tumor aggressiveness and Akt activation in gastric cancer. <i>Oncotarget</i> , 2017, 8, 90948-90958.	1.8	37
106	A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine. <i>Cancer Research and Treatment</i> , 2017, 49, 706-716.	3.0	17
107	Prospective validation of a novel geriatric screening tool, the Korean cancer study group geriatric score (KG)-7, in older patients with advanced cancer undergoing 1st line palliative chemotherapy. <i>Journal of Clinical Oncology</i> , 2017, 35, e21540-e21540.	1.6	0
108	Preoperative chemoradiotherapy for elderly patients with locally advanced rectal cancer: a real-world outcome study. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 1108-1117.	1.3	16

#	ARTICLE	IF	CITATIONS
109	Diffuse Large B-Cell Lymphoma in the Elderly: Real World Outcomes of Immunochemotherapy in Asian Population. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 503-510.e3.	0.4	7
110	Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 42-52.	5.3	230
111	Phase II trial of dacomitinib in patients with HER2-positive gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 1095-1103.	5.3	33
112	Population-based outcomes research on treatment patterns and impact of chemotherapy in older patients with metastatic gastric cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 687-697.	2.5	12
113	A randomized, open-label, two-arm phase II trial comparing the efficacy of sequential ipilimumab (ipi) versus best supportive care (BSC) following first-line (1L) chemotherapy in patients with unresectable, locally advanced/metastatic (A/M) gastric or gastro-esophageal junction (G/GEJ) cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4011-4011.	1.6	34
114	Efficacy and safety findings from DREAM: A phase III study of DHP107 (oral paclitaxel) vs IV paclitaxel in patients with gastric cancer after failure of first-line chemotherapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4016-4016.	1.6	3
115	Multidimensional Geriatric Prognostic Index, Based on a Geriatric Assessment, for Long-Term Survival in Older Adults in Korea. <i>PLoS ONE</i> , 2016, 11, e0147032.	2.5	12
116	Tumor Heterogeneity in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Assessed by CT Texture Analysis: Association with Survival after Trastuzumab Treatment. <i>PLoS ONE</i> , 2016, 11, e0161278.	2.5	44
117	Transmissibility of the Campaign for Colorectal Cancer Awareness in Korea Among Twitter Users. <i>Annals of Coloproctology</i> , 2016, 32, 184.	2.0	12
118	Antitumor Activity of HM781-36B, alone or in Combination with Chemotherapeutic Agents, in Colorectal Cancer Cells. <i>Cancer Research and Treatment</i> , 2016, 48, 355-364.	3.0	7
119	Prospective Study on the Incidence of Postoperative Venous Thromboembolism in Korean Patients with Colorectal Cancer. <i>Cancer Research and Treatment</i> , 2016, 48, 978-989.	3.0	16
120	Efficacy and safety of FOLFIRI regimen in elderly versus nonelderly patients with advanced colorectal and gastric cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 701-701.	1.6	0
121	Clinical outcomes of patients enrolled in clinical trial compared with patients outside clinical trial in advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 21-21.	1.6	0
122	Effect of Smad3/4 on chemotherapeutic drug sensitivity in colorectal cancer cells. <i>Oncology Reports</i> , 2015, 33, 185-192.	2.6	14
123	Effects of a DPP4 inhibitor on cisplatin-induced acute kidney injury: study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 239.	1.6	16
124	Impact of Intratumoral Expression Levels of Fluoropyrimidine-Metabolizing Enzymes on Treatment Outcomes of Adjuvant S-1 Therapy in Gastric Cancer. <i>PLoS ONE</i> , 2015, 10, e0120324.	2.5	7
125	A Novel Geriatric Screening Tool in Older Patients with Cancer: The Korean Cancer Study Group Geriatric Score (KG)-7. <i>PLoS ONE</i> , 2015, 10, e0138304.	2.5	10
126	Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2520-2529.	7.0	59

#	ARTICLE	IF	CITATIONS
127	Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden. <i>Thrombosis Research</i> , 2015, 135, 846-851.	1.7	24
128	A phase I/II trial of second-line chemotherapy with paclitaxel and irinotecan in fluoropyrimidine- and platinum-pretreated patients with advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 1175-1182.	2.3	1
129	Phase I/II Study of Weekly Oraxol for the Second-Line Treatment of Patients With Metastatic or Recurrent Gastric Cancer. <i>Oncologist</i> , 2015, 20, 896-897.	3.7	17
130	INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A study by the Australasian Gastrointestinal Trials Group (AGITG)â€”Final overall and subgroup results.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4003-4003.	1.6	11
131	INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC)â€”A study by the Australasian Gastrointestinal Trials Group (AGITG), first results.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9-9.	1.6	7
132	Five-Year Follow-up Study of Monoclonal Gammopathy of Undetermined Significance in a Korean Elderly Urban Cohort. <i>Cancer Research and Treatment</i> , 2015, 47, 215-220.	3.0	6
133	p21-Activated Kinase 4 (PAK4) as a Predictive Marker of Gemcitabine Sensitivity in Pancreatic Cancer Cell Lines. <i>Cancer Research and Treatment</i> , 2015, 47, 501-508.	3.0	29
134	A phase III study to compare efficacy and safety of DHP107 (oral paclitaxel) versus IV paclitaxel in patients with metastatic or recurrent gastric cancer after failure of first-line chemotherapy (DREAM).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS4138-TPS4138.	1.6	0
135	Salvage Treatment with Intracerebrospinal Fluid Thiotepa in Patients with Leptomeningeal Metastasis After Failure of Methotrexate-based Treatment. <i>Anticancer Research</i> , 2015, 35, 5631-8.	1.1	4
136	Prevalence and Risk Factors for Iron Deficiency Anemia in the Korean Population: Results of the Fifth Korea National Health and Nutrition Examination Survey. <i>Journal of Korean Medical Science</i> , 2014, 29, 224.	2.5	56
137	Metastatic testicular tumor presenting as a scrotal hydrocele: An initial manifestation of pancreatic adenocarcinoma. <i>Oncology Letters</i> , 2014, 7, 1793-1795.	1.8	9
138	The early discontinuation of palliative chemotherapy in older patients with cancer. <i>Supportive Care in Cancer</i> , 2014, 22, 773-781.	2.2	38
139	Gastric cancer with initial bone metastasis: A distinct group of diseases with poor prognosis. <i>European Journal of Cancer</i> , 2014, 50, 2810-2821.	2.8	33
140	Differing effects of adjuvant chemotherapy according to BRCA1 nuclear expression in gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1435-1443.	2.3	15
141	Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival. <i>Gastric Cancer</i> , 2013, 16, 581-589.	5.3	28
142	A Prospective Study on the Incidence of Postoperative Venous Thromboembolism in Korean Gastric Cancer Patients: An Inquiry into the Application of Western Guidelines to Asian Cancer Patients. <i>PLoS ONE</i> , 2013, 8, e61968.	2.5	18
143	A prospective study on the incidence of postoperative venous thromboembolism in Korean gastric cancer patients: An inquiry into the application of western guidelines to Asian cancer patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, e15129-e15129.	1.6	0
144	The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. <i>Cancer Letters</i> , 2008, 272, 296-306.	7.2	111